Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, treatment with flutamide combined with a low-dose oral contraceptive significantly improved hirsutism in women with polycystic ovarian disease who did not respond to oral contraceptive treatment alone.

In this study, baricitinib was found to be effective and safe for treating severe alopecia areata, with significant hair regrowth observed in many patients by the third month of therapy and continued improvement by the twelfth month, despite mostly mild adverse events.

This review highlights that pharmacotherapy for polycystic ovary syndrome should address individual patient concerns, with metformin beneficial for reducing weight and metabolic risk, and lifestyle modifications also important.

This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.

This study found that continuous use of loop diuretics may double the rate of bone loss in elderly men compared to intermittent or non-use.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

This source does not report any results or findings, as no abstract is provided.

This study found that adding calcitriol to metformin significantly improved symptoms in patients with polycystic ovary syndrome and decreased serum MCP-1 levels compared to metformin alone.

In this study, imiquimod was found to increase regression of cervical intraepithelial neoplasia compared to placebo, though it commonly caused side effects that rarely led to treatment discontinuation.

This case report suggests that hair loss may be a potential adverse effect of rivaroxaban, though it is not listed in the product characteristics.

This study found that long-term GnRH agonist administration in premenopausal women with polycystic ovarian disease resulted in persistent suppression of ovarian steroid secretion, while adrenal steroid levels remained unchanged.

This review summarizes various treatment options for polycystic ovary syndrome, noting that while some treatments address specific symptoms, no single therapy fully resolves the condition.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This study found that women with common baldness treated with cyclical antiandrogen therapy for 52 weeks experienced increased hair density and a higher percentage of hairs in the anagen growth phase.

This article highlights that rivaroxaban, commonly associated with bleeding risks, may also cause rare non-bleeding adverse effects like liver injury and hypersensitivity.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

In laboratory tests, this study found that a novel natural composition targeting 5-alpha reductase and inflammatory pathways reduced disease-related markers in androgenetic alopecia and benign prostatic hyperplasia more effectively than finasteride.

This study used molecular docking simulations to identify Adapalene, Diosmin, and Azelastine as promising drugs for repurposing against Onchocerciasis by targeting Onchocerca volvulus and its endosymbiont; further research is suggested to confirm their efficacy.

This article discusses the use of oral contraceptives for treating hyperandrogenism in women, reporting improvement in most patients, especially in reducing new hair growth, but presents no new clinical findings.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

This article discusses the importance of recognizing adverse drug reactions, methods of prevention, and encourages reporting them to the FDA's MedWatch program; it reports no new results.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This study developed a niosomal delivery system loaded with tretinoin and bicalutamide, optimized for follicular targeting in acne management, showing promising accumulation in hair follicles in animal models.

Hormonal contraceptives and related compounds can increase health risks like thrombosis and affect sexual function.

This study found that the oral contraceptive containing drospirenone (EE/DRSP) was as effective as EE/CPA in reducing acne lesions, sebum production, and hair growth in women with acne.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

This review reports that cubosomes, used as drug nanocarriers in topical treatments, offer potential benefits for managing skin and eye diseases by improving bioadhesion, retention, and sustained release compared to conventional formulations, but also face manufacturing and biological challenges for effective clinical outcomes.

In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.